Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment
- 1 July 2004
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 76 (3), 283-285
- https://doi.org/10.1002/ajh.20112
Abstract
Sweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim, a drug that causes increased neutrophil proliferation and differentiation. This complication has not previously been reported during treatment with sargramostim, a hematopoietic cytokine with activity that overlaps filgrastim. We report a case of Sweet's syndrome in association with sargramostim treatment following chemotherapy for acute myelogenous leukemia. A suspected second episode occurred after subsequent chemotherapy and sargramostim treatment. Physicians should be aware of this possible association because the signs and symptoms of Sweet's syndrome are easily mistaken as being due to infection.Keywords
This publication has 4 references indexed in Scilit:
- Sweet’s syndrome accompanying leukaemia: seven cases and review of the literatureLeukemia Research, 2000
- Molecular analysis of the granulocyte colony-stimulating factor receptorBlood, 1996
- Molecular physiology of granulocyte-macrophage colony-stimulating factorBlood, 1991
- AN ACUTE FEBRILE NEUTROPHTLIC DERMATOSTS.British Journal of Dermatology, 1964